If your Current Weight is: Your new weight could be: Average study participant lost 15% *In the STEP 5 trial, participants for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, patients taking semaglutide (typically in doses of 2.4 mg once weekly) for weight management lost an average of about 15% of their body weight over 68 weeks
Lab Work You can either bring in blood work results, or we can administer them in the office if needed
Here at Rivas Medical Weight Loss, we meet with our clients on a weekly basis to help manage their side effects and prevent bowel obstructions

These reviews should assess: Weight loss progress and tolerability Blood glucose control (particularly in diabetic patients) Cardiovascular risk factors Nutritional status and dietary adequacy Any new symptoms or adverse effects Mental health and eating behaviours Patients can optimise safety by: Following the prescribed dose escalation schedule to minimise side effects Maintaining adequate nutrition despite reduced appetite Discussing nutritional needs with a dietitian, particularly if dietary intake is significantly reduced Monitoring blood glucose levels if diabetic, as Wegovy may necessitate adjustment of other diabetes medications Staying well-hydrated, especially if experiencing gastrointestinal side effects Reporting any new or concerning symptoms promptly Healthcare professionals and patients should report suspected adverse reactions through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), contributing to ongoing safety surveillance